Crescent Biopharma (NASDAQ:CBIO) CEO Sells 42,305 Shares of Stock

Posted by Francis Steltz on Jun 23rd, 2026

Crescent Biopharma, Inc. (NASDAQ:CBIO – Get Free Report) CEO Joshua Brumm sold 42,305 shares of the business’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $17.99, for a total transaction of $761,066.95. Following the completion of the sale, the chief executive officer directly owned 281,212 shares of the company’s stock, valued at $5,059,003.88. This represents a 13.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Crescent Biopharma Price Performance

NASDAQ CBIO traded down $0.07 during trading on Tuesday, hitting $17.50. 227,100 shares of the company’s stock traded hands, compared to its average volume of 235,713. The stock has a fifty day moving average of $19.83 and a two-hundred day moving average of $15.01. Crescent Biopharma, Inc. has a 12-month low of $8.72 and a 12-month high of $27.41. The firm has a market cap of $482.30 million, a P/E ratio of -1.60 and a beta of 1.17.

Crescent Biopharma (NASDAQ:CBIO – Get Free Report) last released its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.15. The company had revenue of $1.04 million during the quarter, compared to analysts’ expectations of $0.36 million. As a group, analysts expect that Crescent Biopharma, Inc. will post -3.25 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have commented on CBIO shares. HC Wainwright decreased their price target on Crescent Biopharma from $25.00 to $22.00 and set a “buy” rating on the stock in a research note on Monday, March 2nd. Stifel Nicolaus set a $29.00 target price on shares of Crescent Biopharma in a report on Thursday, February 26th. Weiss Ratings upgraded shares of Crescent Biopharma from a “sell (e)” rating to a “sell (d-)” rating in a report on Wednesday, May 13th. Finally, Wall Street Zen upgraded shares of Crescent Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, March 7th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $29.00.

Check Out Our Latest Research Report on CBIO

Institutional Trading of Crescent Biopharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CBIO. Bank of America Corp DE purchased a new position in Crescent Biopharma during the 2nd quarter valued at $149,000. Cannon Global Investment Management LLC purchased a new stake in shares of Crescent Biopharma in the 1st quarter worth about $187,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of Crescent Biopharma in the 4th quarter worth about $138,000. HRT Financial LP bought a new position in Crescent Biopharma in the fourth quarter worth about $155,000. Finally, Quadrature Capital Ltd bought a new stake in Crescent Biopharma during the 4th quarter valued at approximately $157,000. Hedge funds and other institutional investors own 75.19% of the company’s stock.

Crescent Biopharma Company Profile

(Get Free Report)

Crescent Biopharma, Inc (NASDAQ: CBIO) is a clinical‐stage immuno‐oncology company focused on the discovery, development and commercialization of novel therapies for patients with solid tumors. The company’s research strategy centers on combination approaches that enhance anti‐tumor immune responses by simultaneously targeting multiple pathways implicated in immune evasion and tumor growth.

The company’s lead candidate, CPB-201, is a bifunctional fusion protein designed to block programmed death-ligand 1 (PD-L1) while neutralizing transforming growth factor-beta (TGF-β), with the goal of restoring T-cell activity and reducing tumor fibrosis.